stockrow
Friday 6 November 2026
Export REGN’s income statement to Excel — free account
Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
905.02
2.12
+0.23%
Follow REGN
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
45.15 | 33.92 | 16.50 | 19.38 | 14.75 | 8.26 | 17.78 | 24.43 | 17.42 | 17.90 |
Piotroski F-Score |
6 | 5 | 5 | 4 | 5 | 6 | 5 | 6 | 4 | 5 |
P/S ratio |
8.18 | 6.93 | 7.83 | 6.25 | 6.12 | 4.15 | 6.34 | 7.36 | 5.41 | 5.63 |
Altman Z-Score |
11.15 | 11.51 | 10.41 | 8.71 | 7.65 | 9.32 | 9.67 | 10.45 | 7.85 | 7.49 |
Altman Z″-Score (non-manufacturers) |
5.77 | 7.55 | 8.80 | 8.24 | 8.06 | 10.35 | 10.19 | 10.53 | 9.67 | 9.21 |
P/FCF ratio |
40.82 | 39.31 | 22.24 | 20.50 | 25.95 | 10.22 | 22.71 | 26.33 | 21.60 | 21.44 |
Beneish M-Score |
(2.77) | (2.33) | (2.17) | (2.26) | (2.07) | (1.46) | (2.70) | (2.57) | (2.25) | (2.53) |
P/Operating CF |
101.83 | 71.74 | 55.30 | 52.07 | 42.23 | 28.14 | 44.86 | 88.61 | 60.87 | 68.97 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 77 |
P/B ratio |
8.94 | 6.62 | 4.60 | 3.70 | 4.71 | 3.56 | 3.40 | 3.72 | 2.62 | 2.58 |
Price to Tangible BV |
8.94 | 6.62 | 4.60 | 3.70 | 4.71 | 3.56 | 3.55 | 3.87 | 2.73 | 2.69 |
EV/Sales |
8.04 | 6.81 | 7.42 | 5.87 | 6.19 | 4.02 | 6.05 | 6.86 | 5.07 | 5.32 |
EV/EBITDA |
27.22 | 17.96 | 14.24 | 15.91 | 13.79 | 6.99 | 14.49 | 20.13 | 16.11 | 18.52 |
EV/Operating CF |
26.29 | 30.57 | 17.40 | 15.84 | 20.09 | 9.11 | 14.68 | 19.57 | 16.30 | 15.33 |
EV/FCF |
40.11 | 38.63 | 21.08 | 19.25 | 26.25 | 9.88 | 21.67 | 24.52 | 20.25 | 20.27 |
Quick Ratio |
2.13 | 2.98 | 3.50 | 2.86 | 2.86 | 2.98 | 4.16 | 4.82 | 3.86 | 3.28 |
Current Ratio |
2.56 | 3.82 | 4.47 | 3.67 | 3.63 | 3.56 | 5.06 | 5.69 | 4.73 | 4.13 |
Net Debt/EBITDA |
(0.48) | (0.32) | (0.78) | (1.03) | (0.23) | (0.40) | (0.99) | (1.82) | (1.41) | (1.43) |
Debt/Assets |
5.04% | 8.03% | 6.04% | 4.82% | 15.71% | 7.78% | 9.25% | 8.17% | 7.16% | 6.67% |
Debt/Equity |
0.08 | 0.11 | 0.08 | 0.06 | 0.24 | 0.11 | 0.12 | 0.10 | 0.09 | 0.09 |
Asset Turnover |
0.77 | 0.75 | 0.50 | 0.49 | 0.53 | 0.75 | 0.45 | 0.42 | 0.40 | 0.37 |
Operating CF/Net income |
1.66 | 1.09 | 0.90 | 1.15 | 0.75 | 0.88 | 1.16 | 1.16 | 1.00 | 1.11 |
Capex/Depreciation |
(4.89) | (1.87) | (2.58) | (2.04) | (2.61) | (1.93) | (4.74) | (2.20) | (1.78) | (2.23) |
Interest Coverage |
184.82 | 82.85 | 89.87 | 73.17 | 62.86 | 156.14 | 79.78 | 55.44 | 72.30 | 81.69 |
| 22.10% | 22.63% | 32.81% | 21.32% | 31.77% | 54.21% | 20.94% | 16.26% | 15.95% | 14.87% | |
| 14.23% | 15.23% | 23.85% | 15.94% | 21.98% | 37.91% | 15.88% | 12.69% | 12.46% | 11.50% | |
ROIC |
22.11% | 23.90% | 23.80% | 16.08% | 22.06% | 37.14% | 16.81% | 14.19% | 10.82% | 8.82% |
Return on Tangible Assets |
22.26% | 21.56% | 32.25% | 24.94% | 34.10% | 59.53% | 26.28% | 19.57% | 22.84% | 24.00% |
Average Days of Receivables |
121.03 | 122.72 | 159.12 | 155.05 | 176.75 | 137.09 | 159.78 | 157.70 | 159.65 | 146.10 |
Research and Development Expense of Revenue |
42.22% | 35.34% | 28.54% | 37.36% | 31.15% | 17.80% | 29.51% | 33.84% | 36.14% | 40.79% |
Selling, General and Administrative Expense of Revenue |
24.23% | 22.49% | 21.91% | 20.46% | 15.84% | 11.35% | 17.38% | 20.06% | 20.80% | 18.82% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 |
Share Based Compensation of Revenue |
11.52% | 8.64% | 8.31% | 7.08% | 5.08% | 3.74% | 5.96% | 6.75% | 6.92% | 6.93% |
Graham Net Nets |
0.02 | 0.04 | 0.09 | 0.10 | 0.07 | 0.11 | 0.12 | 0.13 | 0.13 | 0.11 |
Graham Number |
89.67 | 121.12 | 203.33 | 210.38 | 274.82 | 552.66 | 439.24 | 450.47 | 500.23 | 538.44 |
Earnings Yield |
2.21% | 2.95% | 6.06% | 5.16% | 6.78% | 12.11% | 5.62% | 4.09% | 5.74% | 5.59% |
Free Cash Flow Yield |
2.45% | 2.54% | 4.50% | 4.88% | 3.85% | 9.78% | 4.40% | 3.80% | 4.63% | 4.66% |
Revenue per Share |
46.42 | 55.24 | 47.69 | 60.05 | 78.97 | 152.05 | 113.66 | 122.94 | 131.62 | 137.12 |
Operating CF per Share |
14.19 | 12.30 | 20.34 | 22.25 | 24.33 | 66.99 | 46.82 | 43.06 | 40.97 | 47.60 |
Capex per Share |
(4.89) | (2.56) | (3.55) | (3.93) | (5.71) | (5.22) | (15.10) | (8.68) | (7.98) | (11.60) |
Free Cash Flow per Share |
9.30 | 9.73 | 16.79 | 18.32 | 18.62 | 61.77 | 31.73 | 34.37 | 32.98 | 36.00 |
Cash per Share |
9.92 | 13.26 | 26.04 | 29.44 | 33.34 | 53.88 | 72.29 | 101.64 | 83.53 | 82.27 |
Shareholders Equity per Share |
42.50 | 57.80 | 81.16 | 101.55 | 102.47 | 177.57 | 211.62 | 243.42 | 272.04 | 298.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
42.50 | 57.80 | 81.16 | 101.55 | 102.47 | 177.57 | 211.62 | 243.42 | 272.04 | 298.82 |
Free Cash Flow |
974.00 | 1,034.50 | 1,812.00 | 2,000.40 | 2,003.50 | 6,529.40 | 3,398.00 | 3,667.60 | 3,559.00 | 3,765.20 |
Working Capital |
1,938.69 | 3,199.50 | 5,004.80 | 5,592.50 | 7,081.70 | 10,082.40 | 12,742.80 | 16,055.80 | 14,716.60 | 13,653.50 |
Capital Expenditures |
(511.90) | (272.60) | (383.10) | (429.60) | (614.60) | (551.90) | (1,616.90) | (926.40) | (861.50) | (1,213.70) |
Net Current Asset Value |
655.97 | 1,714.80 | 3,470.40 | 3,973.60 | 3,641.10 | 7,348.90 | 9,333.60 | 12,372.10 | 10,255.10 | 8,720.10 |
EV/EBIT |
29.36 | 19.22 | 15.07 | 17.42 | 14.70 | 7.21 | 15.54 | 22.22 | 18.06 | 21.34 |
Capex to Sales |
0.11 | 0.05 | 0.07 | 0.07 | 0.07 | 0.03 | 0.13 | 0.07 | 0.06 | 0.08 |
Price to Operating Income |
29.87 | 19.56 | 15.90 | 18.55 | 14.53 | 7.46 | 16.28 | 23.86 | 19.26 | 22.57 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.11 | 0.11 |
Cash ROIC |
16.68% | 12.53% | 14.76% | 13.32% | 11.58% | 24.69% | 10.26% | 9.28% | 8.67% | 8.85% |
Accounts Receivable Turnover |
3.16 | 3.28 | 2.44 | 2.61 | 2.46 | 3.17 | 2.14 | 2.39 | 2.39 | 2.40 |
Accounts Payable Turnover |
0.39 | 0.75 | 2.11 | 2.40 | 2.51 | 4.69 | 2.71 | 3.04 | 2.82 | 2.43 |
Inventory Turnover |
0.94 | 0.71 | 0.44 | 0.60 | 0.67 | 1.26 | 0.72 | 0.73 | 0.70 | 0.67 |
Average Days of Payables |
1,070.64 | 163.80 | 190.76 | 199.46 | 154.98 | 84.46 | 137.82 | 121.93 | 146.24 | 163.15 |
Days of Inventory on Hand |
486.37 | 667.40 | 1,006.44 | 675.28 | 624.66 | 292.19 | 561.84 | 518.71 | 571.87 | 556.14 |
Average Receivables |
1,539.71 | 1,792.96 | 2,108.75 | 2,514.40 | 3,450.15 | 5,075.60 | 5,682.60 | 5,498.00 | 5,939.60 | 5,976.50 |
Average Payables |
761.60 | 528.65 | 198.20 | 318.15 | 446.80 | 519.75 | 576.60 | 597.90 | 698.05 | 864.25 |
Average Inventory |
318.97 | 562.73 | 938.65 | 1,283.35 | 1,666.05 | 1,933.95 | 2,176.60 | 2,491.20 | 2,833.90 | 3,144.05 |
Average Assets |
6,291.30 | 7,868.88 | 10,249.40 | 13,269.85 | 15,984.25 | 21,299.05 | 27,324.65 | 31,147.35 | 35,419.80 | 39,159.05 |
Average Common Equity |
4,052.04 | 5,296.67 | 7,450.70 | 9,923.50 | 11,057.50 | 14,897.05 | 20,716.40 | 24,318.55 | 27,663.35 | 30,305.25 |
Columns are period end dates · fundamentals updated 5 Nov 2026